Many trials combine chemotherapy, but with EGFR-mutated NSCLC, it will be interesting to see if a combination of ADC with EGFR TKI as studied in HER3-DXd with osimertinib will prove to be more efficacious and not more toxic than ADC monotherapy, and if so, if this combination will be more effective than ADC with chemotherapy (NCT04676477). Here, ERBB3 is linked to non-small cell lung carcinoma.